Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Encapsulated Compounds/ BPC-157 Arginate + TB-500 Capsules
In stock
BPC-157 Arginate + TB-500 Capsules

BPC-157 Arginate + TB-500 Capsules

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

BPC-157 Arginate + TB-500 is a dual-peptide encapsulated blend combining BPC-157 Arginate (the arginine salt form of the 15-amino-acid pentadecapeptide GEPPPGKPADDAGLV; free base CAS 137525-51-0) with TB-500 (a synthetic form of Thymosin Beta-4, CAS 77591-33-4), a 43-amino-acid actin-sequestering peptide studied in wound-healing, angiogenesis, and cytoskeletal modelling. Supplied as pre-measured capsules at HPLC ≥99% purity. For laboratory research use only; not for human or veterinary use.

Two of the most-studied repair peptides in the regeneration literature approach tissue dynamics from opposite ends of the same problem — and this reference article pairs them in a single pre-weighed format. BPC-157 Arginate + TB-500 is a research blend combining the gastric-derived pentadecapeptide BPC-157 (cytoprotection, angiogenesis, nitric-oxide signalling) with TB-500, the synthetic active region of Thymosin β-4 (actin regulation, cell migration). Each is well characterised on its own; here they are co-formulated as one laboratory reference material.

Two distinct mechanisms in one article. BPC-157 is studied as a cytoprotective compound whose effects cluster around angiogenesis and the nitric-oxide system, framed as preserving and recovering essential protective functions (Sikiric et al., 2025), and it recurs across orthopaedic peptide reviews as a tissue-repair candidate (Rahman et al., 2026). TB-500, by contrast, reproduces the G-actin-binding motif of thymosin β-4, a molecule studied for cardiac remodelling and the Rac/F-actin pathway (Maar et al., 2025; Zhang et al., 2025).

The rationale for studying them together is that they engage complementary axes of the repair question — structural cytoprotection versus actin-driven cell motility — making the blend a convenient single reference for comparative experimental work.

What the research explores. Across cell-culture and animal systems, the two components have been investigated along several converging lines:

  • Musculoskeletal repair (BPC-157) — examined in tendon, ligament and muscle-to-bone reattachment models (Matek et al., 2025).
  • Actin regulation & cardiac remodelling (TB-500) — studied through ROCK1 and Rac/F-actin pathways in cardiac and graft-survival systems (Maar et al., 2025; Zhang et al., 2025).
  • Tissue protection & regeneration signalling (both) — explored from cytoprotection and analgesia through to kidney and corneal repair endpoints (Yuan et al., 2026; Di et al., 2026; Nguyen et al., 2025).

The activity described here is drawn from in-vitro and animal studies; it characterises biological behaviour in experimental models and does not establish efficacy or safety in humans. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS No. 137525-51-0 (BPC-157) · 77591-33-4 (TB-500) · Molecular formula C62H98N16O22 + C212H350N56O78S · Molecular weight 1419.55 + 4963.44 g/mol · Sequence BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa) · TB-500: Thymosin β-4 active region (43 aa) · Appearance: White lyophilized powder blend · Solubility: Soluble in water.

Specification & quality. Each bottle contains 60 HPMC (vegan) capsules, each providing 250 + 250 mcg of BPC-157 (arginate) + TB-500 at ≥99% (HPLC). Encapsulated — no reconstitution required. Every batch is independently third-party tested, and a Certificate of Analysis (COA) is available. Store at -20°C, protect from light and moisture; shelf life 24 months from the manufacture date. EU warehoused.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number137525-51-0 (BPC-157) · 77591-33-4 (TB-500)
Molecular formulaC62H98N16O22 + C212H350N56O78S
Molecular weight1419.55 + 4963.44
SequenceBPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa) · TB-500: Thymosin β-4 active region (43 aa)
Purity≥99% (HPLC)
Physical formWhite lyophilized powder blend
Quantity60 capsules
SolubilitySoluble in water
StorageStore at -20°C, protect from light and moisture
ReconstitutionEncapsulated — no reconstitution required.
Shelf life24 months from manufacture date
Dose per capsule250 + 250 mcg
Capsule materialHPMC (Vegan)
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Rahman OF, Lee SJ, Seeds WA Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200. doi:10.5435/JAAOSGlobal-D-25-00236. PubMed 02 Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424. doi:10.1177/03635465251357593. PubMed 03 Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. doi:10.1007/s40279-026-02437-0. PubMed 04 Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences. 2026;27(6). PMID: 41898733. doi:10.3390/ijms27062876. PubMed 05 Di H, Huang J, Zhang D, Ni F, Zheng R, Geng H Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026;195:171467. PMID: 41570941. doi:10.1016/j.peptides.2026.171467. PubMed 06 Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland). 2025;18(2). PMID: 40005999. doi:10.3390/ph18020185. PubMed 07 Maar K, Thatcher JE, Karpov E, Rendeki S, Gallyas F Jr, Bock-Marquette I Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. International journal of molecular sciences. 2025;26(9). PMID: 40362372. doi:10.3390/ijms26094131. PubMed 08 Dekker TJ Editorial Commentary: Testosterone, Growth Hormone, and Vitamin D Supplementation Is Not Routinely Indicated for Orthopaedic Surgery Patients. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2025;41(8):3151-3152. PMID: 39909207. doi:10.1016/j.arthro.2025.01.033. PubMed 09 Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel, Switzerland). 2025;18(10). PMID: 41155565. doi:10.3390/ph18101450. PubMed 10 Zhang X, Lin Y, Li H, Wang Q, Mu D Enhancing fat graft survival: thymosin beta-4 facilitates mitochondrial transfer from ADSCs via tunneling nanotubes by upregulating the Rac/F-actin pathway. Free radical biology & medicine. 2025;228:281-298. PMID: 39761767. doi:10.1016/j.freeradbiomed.2024.12.061. PubMed 11 Demirtaş H, Özer A, Yıldırım AK, Dursun AD, Sezen ŞC, Arslan M Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas, Lithuania). 2025;61(2). PMID: 40005408. doi:10.3390/medicina61020291. PubMed 12 Zhu Z, Liao Y, Mou Q, Liu H, Shen Y, Zhu L et al. Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization. Journal of inflammation research. 2025;18:5791-5809. PMID: 40322536. doi:10.2147/JIR.S492814. PubMed 13 Nguyen J, Verma S, Vuong VT, Queener H, Coulson-Thomas VJ, Gesteira TF Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Investigative ophthalmology & visual science. 2025;66(14):31. PMID: 41235866. doi:10.1167/iovs.66.14.31. PubMed 14 Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, Boban Blagaic A et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1). PMID: 39861766. doi:10.3390/pharmaceutics17010119. PubMed 15 Yu R, Li S, Chen L, Hu E, Chai D, Liu Z et al. Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway. The Journal of pharmacy and pharmacology. 2025;77(4):582-592. PMID: 39579076. doi:10.1093/jpp/rgae143. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

It is a research blend combining two peptides: BPC-157, a gastric-derived pentadecapeptide studied for cytoprotection and angiogenesis (Sikiric et al., 2025), and TB-500, the synthetic active region of thymosin β-4 studied for actin regulation and cell migration (Maar et al., 2025). The two are co-formulated as a single laboratory reference material. Condor Research supplies it strictly as a Research Use Only reference compound for in vitro and animal studies, not for human or veterinary use.

The two peptides engage complementary axes of the tissue-repair question: BPC-157 is studied around cytoprotection and the nitric-oxide system, while TB-500 is studied around actin-driven cell motility and remodelling (Sikiric et al., 2025; Maar et al., 2025). Pairing them in one pre-weighed format gives researchers a convenient single reference for comparative experimental work. The blend is offered solely as a Research Use Only reference compound, not for human or veterinary use.

BPC-157 is a 15-residue gastric pentadecapeptide studied for cytoprotection, angiogenesis and nitric-oxide signalling, whereas TB-500 is a 43-residue thymosin β-4 fragment studied as an actin-binding regulator of cell migration. They belong to different peptide classes and probe different mechanisms within the repair question. Both components are supplied strictly as research-use-only reference materials, not for human or veterinary use.

The single BPC-157 article isolates one mechanism (cytoprotection and NO-linked angiogenesis) at 500mcg per capsule, while this blend pairs BPC-157 with TB-500 at 250 + 250 mcg to let researchers study two complementary repair pathways side by side (Rahman et al., 2026; Maar et al., 2025). The choice depends on whether your experimental design needs one mechanism or a comparative pairing. Both are supplied strictly as Research Use Only reference compounds, not for human or veterinary use.

Yes. Condor Research supplies the BPC-157 + TB-500 blend strictly as a Research Use Only reference compound to professionals and institutions, not as a medicine, supplement or product for human or veterinary use. Buyers are responsible for confirming import legality in their own country. Questions: info@condorresearch.com.

The capsule is a pre-weighed solid format holding 250mcg BPC-157 arginate plus 250mcg TB-500 in an HPMC (vegan) shell, so each unit delivers a precise, handling-ready ratio of both peptides. This removes bench weighing of two separate powders and requires no reconstitution. The format is a laboratory convenience only and does not imply or permit human or veterinary consumption — for research use only.

No. Both peptides are already encapsulated together as a pre-measured solid blend, so no reconstitution is required for handling. Researchers prepare any working solutions according to their own validated experimental protocols. The capsule is a laboratory format only and is not intended for human or veterinary use.

Each bottle contains 60 HPMC (vegan) capsules, with 250mcg BPC-157 arginate + 250mcg TB-500 per capsule at ≥99% (HPLC) purity. Every batch is independently third-party tested and a Certificate of Analysis is available on request. This specification describes a research reference material, not a product for human or veterinary use.

BPC-157 has CAS No. 137525-51-0, molecular formula C62H98N16O22 and a molecular weight of 1419.55 g/mol; TB-500 has CAS No. 77591-33-4, molecular formula C212H350N56O78S and a molecular weight of 4963.44 g/mol. The blend is supplied as a white lyophilized powder, soluble in water. These values are provided for laboratory characterisation and research use only.

Yes. Every BPC-157 + TB-500 batch is tested by an independent third-party laboratory by HPLC for identity and purity (≥99%), and each lot ships with a lot-specific Certificate of Analysis. To request the COA for your batch, contact info@condorresearch.com. This documentation supports research use only, not human or veterinary application.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
77 verified reviews
5
78%
4
16%
3
4%
2
1%
1
1%
Apr 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Mar 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Mar 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase
Feb 2026
Impeccable packaging

Cold-chain handling was respected end to end. Vials arrived sealed, labelled and intact. Documentation is the most thorough I've seen from an EU supplier.

Dr. S. Novak · Private lab · CZ Verified purchase
Jan 2026
Reliable, well documented

Solubility and stability were as described. Knocked one star only because express shipping options are limited, but quality is not in question.

P. Andersson · Research institute · SE Verified purchase

Related compounds